Abstract: Subject of the invention is a composition comprising: (a) at least one film-forming polymer, which does not comprise silicon, (b) at least one organic UV filter, and (c) at least one organic solvent, wherein the composition is liquid at 20° C., wherein components (a) and (b) are dissolved in solvent (c), and wherein the ratio of the total amounts of organic UV filters (b) to film-forming polymers (a) is below 6.5. The invention also relates to compositions for therapy, uses of the composition, devices and methods.

Abstract: Subject of the invention is a composition comprising: (a) at least one film-forming polymer, which does not comprise silicon, (b) at least one organic UV filter, and (c) at least one organic solvent, wherein the composition is liquid at 20° C., wherein components (a) and (b) are dissolved in solvent (c), and wherein the ratio of the total amounts of organic UV filters (b) to film-form ing polymers (a) is below 6.5. The invention also relates to compositions for therapy, uses of the composition, devices and methods.

Abstract: The invention relates to compositions in the form of microemulsion preconcentrates that contain (a) a mixture that consists of a medium-chain triglyceride and an omega-9 fatty acid and/or an omega-6 fatty acid; and (b) a surface-active component that contains a polyoxethylene tenside. When contacted with water or with an aqueous medium these microemulsion preconcentrates form microemulsions. The microemulsions of the O/W type have an average particle size below 150 nm, preferably below 100 nm. The inventive microemulsion preconcentrates and microemulsions are suitable for use as vehicles for substances, namely active agents, that are hardly soluble in water, but soluble in components (a) and/or (b). In the aqueous phase, said microemulsions may contain water-soluble substances.

Abstract: A nanodispersion comprises (a) a membrane-forming molecule, (b) a coemulsifier and (c) a lipophilic component, in pharmaceutical end formulations, the nanodispersion being obtainable by (?) mixing the components (a), (b) and (c) until a homogeneous clear liquid is obtained, and (?) adding the liquid obtained in step (?) to the water phase of the pharmaceutical end formulations, where steps (?) and (?) may be carried out without high energy mixing or homogenization. The nanodispersions prepared according to this invention are suitable as transport vehicles for pharmaceutical active agents.

Abstract: The present invention relates to novel active ingredient formulations in the form of microemulsion products, to processes for the preparation thereof and to the use thereof as carrier system for therapeutic active ingredients which are slightly soluble in water. The formulations of the invention are particularly suitable for oral administration.

Abstract: The present invention relates to a novel pharmaceutical formulation for the topical application of drugs, particularly non-steroidal anti-inflammatory drugs (NSAID's), comprising a therapeutically effective amount of a drug, sodium phosphate buffer, and, optionally, an alcoholic solvent. It has been found that by the addition of sodium phosphate buffer to such formulations, the permeation of the NSAID can be significantly improved.

Abstract: The invention relates to conjugates of lipids and basic, membrane disturbing peptides, particularly compounds of the formula(R--CONH).sub.n --R.sup.3 (I)and(R--S--S).sub.n --R.sup.3 (II)wherein R is the hydrocarbyl moiety of a straight-chain or branched-chain, saturated or unsaturated aliphatic carboxylic acid, or a phospholipid moiety having a free valence bond; R.sup.3 is a basic membrane disturbing peptide having a free valence bond at one or two carbon atom(s); and n is 1 or 2. These conjugates can be used as a vector for transfecting a cell with a polynucleotide or any other anionic macromolecule.

Abstract: Compounds of the formulaR.sup.1 --NH--A Iwherein R.sup.1 is an acyl moiety of a C.sub.12-40 aliphatic carboxylic acid, A is the residue of a oligopeptide devoid of one amino group, and --NH--A contains at least one positively charged amino acid, or derivatives thereof can be used for transferring anionic macromolecules into cells.

Abstract: A controlled release pharmaceutical composition comprising a physiologically active agent dispersed in preformed porous polymeric microparticles is provided. The active agent concentration may be up to about 10% by weight to achieve controlled release. Each of the porous microparticles has a plurality of preformed pores into which active agent is loaded and from which the active agent is subsequently released to the environment of use. The compositions are capable of delivering physiologically effective amounts of active agent for at least about thirty days, which delivery may be reversibly controlled by exposure to ultrasound.

Abstract: Topical preparations containing a salt of a cholanic acid, a lipid, and optionally, one or more other pharmaceutically or cosmetically active substances, are disclosed. These preparations are used in pharmaceutical and/or cosmetic applications.